High-grade serous ovarian cancer, the most common form of the disease, is often fatal. This study investigated the genomic and immune characteristics of tumors from women who survived more than 10 years after their initial diagnosis, and compared them with short-term and moderate-term survivors.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Candido-dos-Reis, F. J. et al. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin. Cancer Res. 21, 652–657 (2015). This paper reports that initial survival advantage in BRCA1/2 mutation carriers decreases over time in women with ovarian cancer.
Dao, F. et al. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol. Oncol. 141, 260–263 (2016). This article describes the clinical features of 10-year survivors of high-grade serous ovarian cancer.
Hoppenot, C. et al. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol. Oncol. 148, 204–212 (2018). This review article summarizes the clinical and genetic factors associated with the long-term survival of high-grade serous ovarian cancer.
Saner, F. A. M. et al. Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nat. Rev. Cancer 19, 339–348 (2019). This review article outlines current studies into exceptional treatment responses and survival in patients with cancer, and considers approaches to identify and analyze these patients.
Nguyen, L. et al. Pan-cancer landscape of homologous recombination deficiency. Nat. Commun. 11, 1–12 (2020). This paper presents a pan-cancer whole-genome sequence analysis tool to classify homologous recombination deficiency and discriminate BRCA1- and BRCA2-type loss.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Garsed, D. W. et al. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nat. Genet. https://doi.org/10.1038/s41588-022-01230-9 (2022).
Rights and permissions
About this article
Cite this article
Beating the odds: molecular characteristics of long-term survivors of ovarian cancer. Nat Genet 54, 1780–1781 (2022). https://doi.org/10.1038/s41588-022-01234-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-022-01234-5
